Missing both earnings and sales estimates, especially when compared to the previous year's performance, typically leads to negative investor sentiment and can result in a short-term decrease in stock price. The reported decline in both key financial metrics emphasizes the potential for a negative impact on Regeneron's stock price in the short term.